Introduction for the Pharmacovigilance standard documents

These seven procedures are internal Sponsor pharmacovigilance unit procedures. They describe how the pharmacovigilance unit organises various activities such as safety data processing, submissions, or periodic safety reports/analyses. If you don't use a separated pharmacovigilance unit for your project, you don't need these procedures.

endTB and endTB-Q Safety Event Reporting Tracker

Safety Event Reporting Tracker.

This excel template allows you to track all reportable safety events such as serious adverse events, adverse events of special interest, overdoses, pregnancies. It summarises which reportable events occurs in which patient, when the reportable event was sent to the various recipients (PV unit, Ethics Committees etc.) and allows you to track whether the site still needs to follow-up on that event or whether it is closed. We recommend the tracker is customzed to your needs.

Target user: All

How to identify easily AESI

Summary with examples illustrating adverse events of special interest situations reportable in the study.

If your project includes the reporting of adverse events of special interest with specific definitions, it can be helpful to have a 1-2 pager summarizing how to identify these adverse events of special interest. This was a request from the site doctors.

Target user: TB doctors

PV-001-CT Safety data collection and reporting at trial sites

Study site procedure describing how to collect and report safety data. 

Study site procedure describing how to collect and report safety data including serious adverse events, adverse events of special interest, pregnancies, overdoses and also periodic reports and safety signals. Reporting to the Sponsor pharmacovigilance unit, Ethics Committees, Data and Safety Monitoring Boards, National Regulatory Agencies is described.

Target user: Study coordinators and TB doctors (investigators)

PV-TB-D18 Safety data reconciliation plan endTB and endTB-Q CTsSafety data reconciliation plan

An annex to the safety data reconciliation procedure that summarizes. 

In link with the procedure on safety data reconciliation, in our project we chose to have the safety data reconciliation plan separated from the procedure to ease changes in dates/planning/scope/mapping information. You can choose to integrate all in a procedure if more convenient for your project.

Target user: Sponsor and study site coordinator

PV-TB-D21 FAQ Severity Grading Scale

Severity grading scale "frequently asked questions" document. 

The Pharmacovigilance unit has gathered the frequently asked questions from doctors on the severity grading and the use of severity grading scale (PV-TB-D12) and gathered answers into this document to be used in conjunction with the severity grading scale. If you have more questions please feel free to contact us as indicated in the FAQ.

Target user: All

PV-TB-D22 Reporting guideline - endTB and endTB-Q interventional clinical trials

Recapitulation of all local (country/site) safety reporting obligations.

This document gathers all local safety reporting requirements for the study from the various local Ethics Committees and local regulatory authorities. It is very helpful in an international multi-site study. If you plan a study with 1 site, it is probably not necessary to use this template as you can describe all the details of the process in the SOP (PV-001-CT) directly.

Target user: Sponsor and study site coordinator

PV-TB-D23 Safety monitoring Plan endTB and endTB-Q Clinical Trial

Recapitulation of all safety monitoring processes for the study.

In a complex study with several different safety monitoring processes, we recommend a safety monitoring plan summarizes all activities in a comprehensive manner. This document can be used to answer inquiries on safety monitoring in the study from Ethics Committees and Regulatory Agencies.

Target user: Sponsor and study site coordinator

PV-TB-F01 MSF SAE report form

MSF SAE Report Form

This form allows you to capture relevant information on Serious Adverse Events occurring in study participants. We also used the same form for Adverse Events of Special Interest and Overdoses in the study (see PV-TB-D01 for details on how to capture). This form is filled by the site doctor and can be used for reporting to the Pharmacovigilance unit but also reporting to Ethics Committees and National Regulatory Agencies if accepted. 

Target user: TB doctors

PV-TB-F02 MSF Pregnancy report form

MSF Pregnancy Report Form

This form allows you to capture relevant information on participant or participant's partner who became pregnant during the study. Collection of partner's pregnancy (e.g., the wife of a male participant becomes pregnant during the husband study participation) is up for you to decide if applicable to your project (e.g., suspicion of male reproductive toxicity).

Target user: TB doctors

PV-TB-P02 Safety Database Administration

Internal pharmacovigilance unit procedure detailing safety (pharmacovigilance) database administration.

If you use a safety/pharmacovigilance database, it is recommended to detail in a procedure how the database is administered. This simple procedure can be used as a template.

Target user: Sponsor pharmacovigilance officer

PV-TB-P04 Compliance Measurement

Internal pharmacovigilance unit procedure detailing how compliance with pharmacovigilance processes is monitored and documented.

If you don't use a pharmacovigilance unit/department at Sponsor level, you can use the same process as in SM-005-CT. If you have a pharmacovigilance unit, you will need a dedicated compliance process that can be the same as we used in this SOP or similar to the study deviation process.

Target user: Sponsor pharmacovigilance officer

PV-TB-P06 Periodic Safety Reports

Internal pharmacovigilance unit procedure detailing how periodic safety reports are prepared, reviewed and submitted.

This procedure can be used as a template to define your process to gather data, write, review and submit periodic safety reports such as annual safety reports or 6-monthly safety reports.

Target user: Sponsor pharmacovigilance officer

PIH MSF MSF Unitaid: Save Lives Faster Médecins Sans Frontières (MSF) Transformational Investment Capacity (TIC) logo